Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail takes on Hard-to-Treat cancers

NCT ID NCT05853367

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how the body handles the drugs. About 178 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-0472 (an experimental drug), pembrolizumab (Keytruda), and MK-1084 (another experimental drug)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will work. Side effects are possible, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS METASTATIC SOLID TUMORS

Contacts and locations

Locations

  • Bradfordhill ( Site 0702)

    Santiago, Region M. de Santiago, 8420383, Chile

  • Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201)

    Sankt Gallen, Canton of St. Gallen, 9000, Switzerland

  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100)

    Montreal, Quebec, H2X 0A9, Canada

  • Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0504)

    Madrid, Madrid, Comunidad de, 28050, Spain

  • Centro de Estudios Clínicos SAGA ( Site 0701)

    Santiago, Region M. de Santiago, 7500653, Chile

  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703)

    Santiago, Region M. de Santiago, 8330034, Chile

  • Département clinique de médecine de laboratoire du CHUM ( Site 0104)

    Montreal, Quebec, H3T 1E2, Canada

  • Fundacion Arturo Lopez Perez ( Site 0700)

    Santiago, Region M. de Santiago, 7500921, Chile

  • Hospital Universitari Vall d'Hebron ( Site 0500)

    Barcelona, 08035, Spain

  • Hospital Virgen del Rocio ( Site 0503)

    Seville, 41013, Spain

  • Hôpitaux Universitaires de Genève (HUG) ( Site 0202)

    Geneva, Canton of Geneva, 1211, Switzerland

  • Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 0501)

    L'Hospitalet de Llobregat, Catalonia, 08907, Spain

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)

    Hackensack, New Jersey, 07601, United States

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Northwestern Memorial Hospital ( Site 0002)

    Chicago, Illinois, 60611, United States

  • Ospedale Regionale Bellinzona e Valli ( Site 0200)

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Princess Margaret Cancer Centre ( Site 0101)

    Toronto, Ontario, M5G 2M9, Canada

  • Rabin Medical Center ( Site 0301)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0304)

    Haifa, 3109601, Israel

  • Rutgers Cancer Institute of New Jersey ( Site 0005)

    New Brunswick, New Jersey, 08901, United States

  • Shaare Zedek Medical Center ( Site 0303)

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0300)

    Ramat Gan, 5265601, Israel

  • Sourasky Medical Center ( Site 0302)

    Tel Aviv, 6423906, Israel

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)

    Louisville, Kentucky, 40202, United States

  • Uniwersyteckie Centrum Kliniczne ( Site 0400)

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.